Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza G P, Ercolani G, Pinna A D, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo M A
Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Department of Radiology, S. Orsola Malpighi Hospital, Bologna University, Bologna, Italy.
Clin Sarcoma Res. 2017 Jan 10;7:1. doi: 10.1186/s13569-016-0065-z. eCollection 2017.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines.
Here we report two patients affected by metastatic GIST, treated with radiotherapy and radiosurgery in combination with TKIs, achieving an unexpected objective response in the first case and a significant clinical benefit associated with a local tumor control of several months in the second case.
These and other successful experiences that are progressively accumulating, open up new scenarios of use of radiation therapy in various settings of treatment. GIST is not universally radioresistant and radiotherapy, especially if combined with molecularly targeted therapy, can improve the outcomes for patients diagnosed with GIST.
胃肠道间质瘤(GIST)是胃肠道最常见的间叶性肿瘤。局限性胃肠道间质瘤的主要治疗方法是手术切除。不可切除或晚期GIST对传统细胞毒性化疗反应不佳,但酪氨酸激酶抑制剂(TKIs)的引入标志着这些患者治疗的革命性进展,从根本上改善了预后和临床获益。从历史上看,GIST一直被认为对放疗耐药,目前治疗指南中放疗在GIST患者管理中的作用仅限于对症姑息治疗。
在此,我们报告两名转移性GIST患者,接受了放疗和放射外科联合TKIs治疗,第一例患者取得了意外的客观缓解,第二例患者获得了显著的临床获益,局部肿瘤控制达数月之久。
这些以及其他逐渐积累的成功经验,为放疗在各种治疗场景中的应用开辟了新的前景。GIST并非普遍对放疗耐药,放疗,尤其是与分子靶向治疗联合应用时,可改善GIST患者的治疗结局。